Menu
Not yet recruiting NCT07509996

Risk Factors Affecting Growth in Thalassemic Children at AUCH

Observational Thalassemia Majors (Beta-Thalassemia Major)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Non-interventional assessment of growth and risk factors in thalassemic children.
Who it may be relevant to
Registry conditions: Thalassemia Majors (Beta-Thalassemia Major). Basic parameters: 12 months — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effect of Different Risk Factors on Growth Parameters of Thalassemic Patients in Assiut University Children Hospital

Overview

Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.

Interventions

  • Other Non-interventional assessment of growth and risk factors in thalassemic children
    No therapeutic intervention is applied. The study involves only observational assessment of clinical history, anthropometric measurements, laboratory investigations, and growth parameters in thalassemic children. This distinguishes it from interventional studies.

Primary outcome measures

  • Growth parameters: Z-scores for height-for-age, weight-for-age, BMI-for-age [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).
  • Receiving regular blood transfusions as part of standard management at AUCH.
  • Attending the hematology unit for at least one year prior to enrollment.

Exclusion criteria

  • • Children with other types of thalassemia.
  • Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.
  • Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07509996 · AUCH-TP-2026-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗